DAX25.383 +0,5%Est506.006 +0,2%MSCI World4.343 -0,1%Top 10 Crypto12,29 +2,1%Nas23.696 +0,1%Bitcoin78.312 +0,2%Euro1,1683 +0,4%Öl63,48 +0,7%Gold4.620 +2,4%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 NVIDIA 918422 Novo Nordisk A3EU6F Deutsche Telekom 555750 TKMS thyssenkrupp Marine Systems TKMS00 Bayer BAY001 DroneShield A2DMAA Allianz 840400 RENK RENK73 Siemens Energy ENER6Y Amazon 906866 BASF BASF11 Lufthansa 823212 Infineon 623100 Volkswagen (VW) vz. 766403
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX etwas höher -- Wall Street uneins -- Eli Lilly plant wohl Abivax-Übernahme -- NVIDIA, VW, Mercedes, Novo Nordisk, Rüstungsaktien, Amazon, DroneShield, Airbus, BYD im Fokus
Top News
Ausblick: JPMorgan Chase legt die Bilanz zum abgelaufenen Quartal vor Ausblick: JPMorgan Chase legt die Bilanz zum abgelaufenen Quartal vor
NVIDIA-Aktie im Fokus: Chip-Riese greift wohl auf alte Hardware zurück NVIDIA-Aktie im Fokus: Chip-Riese greift wohl auf alte Hardware zurück
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
10 DAX-Trends für 2026: Diese Börsentrends erwarten Aktienmarktanalysten für 2026. Starten Sie gut informiert ins neue Börsenjahr. Jetzt lesen!

Ionis Pharmaceuticals Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
68,70 EUR -0,20 EUR -0,29 %
STU
80,62 USD +0,26 USD +0,32 %
BTT
Ionis Pharmaceuticals jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.11,13 Mrd. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2ACMZ

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS4622221004

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolIONS

Ionis Pharmaceuticals Aktien News

DatumMeistgelesen
PR NewswireIonis enters new chapter in 2025 as commercial-stage biotech with multiple independent product launches anticipated and continued late-stage pipeline momentum
PR NewswireIonis to present at 43rd Annual J.P. Morgan Healthcare Conference
PR NewswireTRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet
Wer­bungIonis Pharmaceuticals-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireIonis to present at upcoming investor conferences
PR NewswireIonis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome
PR NewswireIonis reports third quarter 2024 financial results
PR NewswireIonis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE
PR NewswireIonis to hold third quarter 2024 financial results webcast
PR NewswireWAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis
PR NewswireNew positive donidalorsen data to be presented at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
PR NewswireZilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease
PR NewswireIonis to present at upcoming investor conferences
PR NewswireIonis reports second quarter 2024 financial results
PR NewswireAlcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx™ System for Administration of nusinersen
PR NewswireIonis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome
PR NewswireIonis to hold second quarter 2024 financial results webcast
PR NewswireIonis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander disease
PR NewswireIonis announces webcast to report HALOS study results for ION582 in Angelman syndrome
PR NewswireIonis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed
PR NewswireIonis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema
PR NewswireIonis to present at TD Cowen Genetic Medicines & RNA Summit
PR NewswireIonis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema
PR NewswireIonis to hold donidalorsen Phase 3 data webcast
PR NewswireNew data from the Phase 3 NEURO-TTRansform study evaluating WAINUA™ (eplontersen) to be presented at the 2024 International Symposium on Amyloidosis (ISA)
PR NewswireIonis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
PR NewswireIonis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome
PR NewswireIonis to host 2024 virtual Annual Meeting of Stockholders
PR NewswireIonis reports first quarter 2024 financial results
PR NewswireIonis Publishes 2023 Corporate Responsibility Report
PR NewswireIonis to hold first quarter 2024 financial results webcast
PR NewswireIonis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome
PR NewswireIonis to present at upcoming investor conferences
PR NewswireIonis to hold olezarsen Phase 3 data webcast
PR NewswirePositive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting
PR NewswireIonis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH
PR NewswireIonis announces new chief global product strategy officer to lead next phase of commercial growth
PR NewswireIonis to present at upcoming investor conferences
PR NewswireIonis reports fourth quarter and full year 2023 financial results
PR NewswireOlezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome
PR NewswireEplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy

Ionis Pharmaceuticals News

Ionis Pharmaceuticals News: auf dieser Seite finden Sie alle Ionis Pharmaceuticals News und Nachrichten zur Ionis Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Ionis Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Ionis Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.